SMShotaro Michinaga

Shotaro Michinaga

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shotaro Michinaga has a total of 78 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Endothelin-1 induces Zfp36 family RNA-binding proteins and restrains cytokine and chemokine production in reactive astrocytes

    by Yutaka Koyama, Aina Nishiuma, Nagi Takahashi, Eri Izumikawa, Chisato Hamada, Yasuhiko Izumi, Shigeru Hishinuma, Shotaro Michinaga

  • Open Access

    Histamine H1 Receptor-Mediated CREB Phosphorylation via Gq Protein Signaling and Arrestin Modulation

    by Ryosuke Ogami, Shotaro Michinaga, Yosuke Iiboshi, Yasuhiro Ogawa, Shigeru Hishinuma

    Background/Objectives: Histamine H1 receptors mediate multiple physiological and pathophysiological processes, including inflammation and allergy, by regulating downstream gene expression via transcription factors. cAMP response element-binding protein (CREB) is a major transcription factor whose phosphorylation is regulated by multiple signaling pathways. Although CREB is closely involved in multiple physiological and pathophysiological processes, the detailed intracellular signaling pathway of H1 receptor-mediated CREB phosphorylation remains to be elucidated. We investigated the roles of Gq proteins and arrestins in H1 receptor-mediated CREB phosphorylation. Methods: We constructed Chinese hamster ovary (CHO) expressing human wild-type (WT) H1 receptors and two types of C-terminal mutants. One mutant was constructed by truncating the serine 487 residue only at the C-terminus (S487Trunc), and the other was constructed by substituting the serine 487 residue at the C-terminus with alanine (S487A). S487Trunc is a Gq protein-biased while S487A is an arrestin-biased receptor. The expressions of CREB and its phosphorylated form were assessed by immunoblotting. Results: Histamine promoted CREB phosphorylation in CHO cells expressing WT or S487Trunc receptors, but not in cells expressing S487A. Inhibitors of protein kinase C (PKC), extracellular signal-regulated kinase (ERK), or c-Jun N-terminal kinase (JNK), and Ca2+ chelator suppressed histamine-induced CREB phosphorylation in CHO cells expressing WT or S487Trunc receptors. Basal CREB phosphorylation levels increased following β-arrestin overexpression and decreased after their siRNA-mediated knockdown, thus modulating histamine-stimulated CREB phosphorylation in WT CHO cells. Conclusions: H1 receptor-mediated CREB phosphorylation is induced through Gq protein/Ca2+/PKC-dependent ERK and JNK activation; arrestins can modulate this process by regulating basal CREB phosphorylation.

  • Open Access

    Smoothened Agonist Treatment Mitigates Vasogenic Edema, Neuroinflammation, and Neurological Dysfunction Following Traumatic Brain Injury in Mice

    by Shotaro Michinaga, Kenta Takahashi, Yasuhiro Ogawa, Hiroyuki Mizuguchi, Shigeru Hishinuma

    Traumatic brain injury (TBI)—a serious brain damage caused by accidents, falls, and sports—causes vasogenic edema, neuroinflammation, and neurological dysfunction resulting from blood–brain barrier disruption. Sonic hedgehog (Shh), a secretory protein belonging to the hedgehog family, protects cerebrovascular and neuronal function via the patched‐1 (Ptch‐1)–smoothened (Smo)–Gli pathway. In this study, we investigated the effects of Smo agonists (Shh and SAG) and antagonist (Jervine) on vasogenic edema, neuroinflammation, and neurological dysfunction in mice following TBI. Male ddy mice (8 weeks old) were used to minimize the influence of gonadal hormones on the results. A TBI model was established by inflicting a fluid percussion injury (FPI) on mouse cerebrum or cultured cells. Shh expression increased in mouse cerebrums and cultured astrocytes after FPI. Vasogenic edema was assessed by Evans blue extravasation into brain tissue and increased brain water content. Evans blue extravasation and brain water content increased after FPI. Repeated intracerebroventricular administration of recombinant Shh reduced Evans blue extravasation and brain water content in the cerebrum after FPI, whereas treatment with Jervine, an Smo antagonist, aggravated these conditions. Recombinant Shh administration also decreased the expression of inflammatory cytokines and chemokines in the cerebrum after FPI. Notably, repeated intravenous administration of SAG, a small‐molecule Smo agonist, reduced FPI‐induced vasogenic edema and neuroinflammation, and improved neurological dysfunction in mice. Furthermore, SAG treatment increased the expression of vascular protective factors and tight junction proteins. These results suggest that Smo agonists are promising therapeutic agents for TBI.


  • Endothelin‐1 increases Na + ‐K + ‐ 2Cl − cotransporter‐1 expression in cultured astrocytes and in traumatic brain injury model: An involvement of HIF1α activation

    by Yutaka Koyama, Yasuhiro Hamada, Yura Fukui, Nami Hosogi, Rina Fujimoto, Shigeru Hishinuma, Yasuhiro Ogawa, Kenta Takahashi, Yasuhiko Izumi, Shotaro Michinaga

    Na + ‐K + ‐2Cl − cotransporter‐1 (NKCC1) is present in brain cells, including astrocytes. The expression of astrocytic NKCC1 increases in the acute phase of traumatic brain injury (TBI), which induces brain edema. Endothelin‐1 (ET‐1) is a factor that induces brain edema and regulates the expression of several pathology‐related genes in astrocytes. In the present study, we investigated the effect of ET‐1 on NKCC1 expression in astrocytes. ET‐1 (100 nM)‐treated cultured astrocytes showed increased NKCC1 mRNA and protein levels. The effect of ET‐1 on NKCC1 expression in cultured astrocytes was reduced by BQ788 (1 μM), an ET B antagonist, but not by FR139317 (1 μM), an ET A antagonist. The involvement of ET‐1 in NKCC1 expression in TBI was examined using a fluid percussion injury (FPI) mouse model that replicates the pathology of TBI with high reproducibility. Administration of BQ788 (15 nmol/day) decreased FPI‐induced expressions of NKCC1 mRNA and protein, accompanied with a reduction of astrocytic activation. FPI‐induced brain edema was attenuated by BQ788 and NKCC1 inhibitors (azosemide and bumetanide). ET‐1‐treated cultured astrocytes showed increased mRNA and protein expression of hypoxia‐inducible factor‐1α (HIF1α). Immunohistochemical observations of mouse cerebrum after FPI showed co‐localization of HIF1α with GFAP‐positive astrocytes. Increased HIF1α expression in the TBI model was reversed by BQ788. FM19G11 (an HIF inhibitor, 1 μM) and HIF1α siRNA suppressed ET‐induced increase in NKCC1 expression in cultured astrocytes. These results indicate that ET‐1 increases NKCC1 expression in astrocytes through the activation of HIF1α.


  • Open Access

    Histamine H1 Receptor-Mediated JNK Phosphorylation Is Regulated by Gq Protein-Dependent but Arrestin-Independent Pathways

    by Shotaro Michinaga, Ayaka Nagata, Ryosuke Ogami, Yasuhiro Ogawa, Shigeru Hishinuma

    Arrestins are known to be involved not only in the desensitization and internalization of G protein-coupled receptors but also in the G protein-independent activation of mitogen-activated protein (MAP) kinases, such as extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK), to regulate cell proliferation and inflammation. Our previous study revealed that the histamine H1 receptor-mediated activation of ERK is dually regulated by Gq proteins and arrestins. In this study, we investigated the roles of Gq proteins and arrestins in the H1 receptor-mediated activation of JNK in Chinese hamster ovary (CHO) cells expressing wild-type (WT) human H1 receptors, the Gq protein-biased mutant S487TR, and the arrestin-biased mutant S487A. In these mutants, the Ser487 residue in the C-terminus region of the WT was truncated (S487TR) or mutated to alanine (S487A). Histamine significantly stimulated JNK phosphorylation in CHO cells expressing WT and S487TR but not S487A. Histamine-induced JNK phosphorylation in CHO cells expressing WT and S487TR was suppressed by inhibitors against H1 receptors (ketotifen and diphenhydramine), Gq proteins (YM-254890), and protein kinase C (PKC) (GF109203X) as well as an intracellular Ca2+ chelator (BAPTA-AM) but not by inhibitors against G protein-coupled receptor kinases (GRK2/3) (cmpd101), β-arrestin2 (β-arrestin2 siRNA), and clathrin (hypertonic sucrose). These results suggest that the H1 receptor-mediated phosphorylation of JNK is regulated by Gq-protein/Ca2+/PKC-dependent but GRK/arrestin/clathrin-independent pathways.


  • Open Access

    Roles of Astrocytic Endothelin ETB Receptor in Traumatic Brain Injury

    by Shotaro Michinaga, Shigeru Hishinuma, Yutaka Koyama

    Traumatic brain injury (TBI) is an intracranial injury caused by accidents, falls, or sports. The production of endothelins (ETs) is increased in the injured brain. ET receptors are classified into distinct types, including ETA receptor (ETA-R) and ETB receptor (ETB-R). ETB-R is highly expressed in reactive astrocytes and upregulated by TBI. Activation of astrocytic ETB-R promotes conversion to reactive astrocytes and the production of astrocyte-derived bioactive factors, including vascular permeability regulators and cytokines, which cause blood–brain barrier (BBB) disruption, brain edema, and neuroinflammation in the acute phase of TBI. ETB-R antagonists alleviate BBB disruption and brain edema in animal models of TBI. The activation of astrocytic ETB receptors also enhances the production of various neurotrophic factors. These astrocyte-derived neurotrophic factors promote the repair of the damaged nervous system in the recovery phase of patients with TBI. Thus, astrocytic ETB-R is expected to be a promising drug target for TBI in both the acute and recovery phases. This article reviews recent observations on the role of astrocytic ETB receptors in TBI.


  • Open Access

    Selective histamine H2 receptor agonists alleviate blood-brain barrier disruption by promoting the expression of vascular protective factors following traumatic brain injury in mice

    by Shotaro Michinaga, Kiyomi Sonoda, Naoki Inazuki, Manae Ezaki, Hiroki Awane, Kahori Shimizu, Shigeru Hishinuma, Hiroyuki Mizuguchi


  • Top Cited Papers
    Open Access

    Pathophysiological Responses and Roles of Astrocytes in Traumatic Brain Injury

    by Shotaro Michinaga, Yutaka Koyama

    Traumatic brain injury (TBI) is immediate damage caused by a blow to the head resulting from traffic accidents, falls, and sporting activity, which causes death or serious disabilities in survivors. TBI induces multiple secondary injuries, including neuroinflammation, disruption of the blood–brain barrier (BBB), and brain edema. Despite these emergent conditions, current therapies for TBI are limited or insufficient in some cases. Although several candidate drugs exerted beneficial effects in TBI animal models, most of them failed to show significant effects in clinical trials. Multiple studies have suggested that astrocytes play a key role in the pathogenesis of TBI. Increased reactive astrocytes and astrocyte-derived factors are commonly observed in both TBI patients and experimental animal models. Astrocytes have beneficial and detrimental effects on TBI, including promotion and restriction of neurogenesis and synaptogenesis, acceleration and suppression of neuroinflammation, and disruption and repair of the BBB via multiple bioactive factors. Additionally, astrocytic aquaporin-4 is involved in the formation of cytotoxic edema. Thus, astrocytes are attractive targets for novel therapeutic drugs for TBI, although astrocyte-targeting drugs have not yet been developed. This article reviews recent observations of the roles of astrocytes and expected astrocyte-targeting drugs in TBI.


  • Open Access

    The effects of ambrisentan, a selective endothelin ETA receptor antagonist for vasogenic edema after traumatic brain injury in mice

    by Shotaro Michinaga, Ryotaro Ryu, Hayato Yamamoto, Hiroyuki Mizuguchi, Yutaka Koyama

    Vasogenic edema is a severe condition resulted from disruption of blood-brain barrier (BBB) after traumatic brain injury (TBI). Endothelin (ET) is an aggravating factor for the BBB disruption. In this study, we confirmed the effects of ambrisentan, an ETA receptor antagonist for TBI-induced vasogenic edema. As a model of TBI, mice (male ddY, 6 to 7 weeks) were given fluid percussion injury (FPI) by hydraulic impact on dura mater. Ambrisentan (0.02, 0.1 and 0.5 mg/kg/day) were repeatedly administrated from mouse tail vein in 6 hour to 2 days after FPI. To evaluate vasogenic edema, the BBB disruption and brain edema were evaluated by Evans blue extravasation and brain water content, respectively. Expressions of vascular endothelial growth factor-A (VEGF-A) as an aggravating factor for the BBB disruption and angiopoietin-1 (ANG-1) as a protective factor were measured by Real-time PCR. Expression of ETA receptors was observed by immunohistochemistry. The i.v. administrations of ambrisentan ameliorated the BBB disruption and decreased in brain water content in 2 day after FPI. Ambrisentan decreased in VEGF-A and increased in ANG-1 after FPI. The immunochemical observations indicated that ETA receptors were distributed in brain endothelial cells in mouse cerebrum. In vitro experiments, treatment with ET-1 (100 nM) increased in VEGF-A and decreased in ANG-1 in brain endothelial cells (bEnd.3 cells). Treatment with ambrisentan (1 μM) inhibited the effects of ET-1. These results suggest that ambrisentan is expected to be a novel therapeutic drug for vasogenic edema.

  • Open Access

    Endothelin-1 stimulates expression of cyclin D1 and S-phase kinase–associated protein 2 by activating the transcription factor STAT3 in cultured rat astrocytes

    by Yutaka Koyama, Satoshi Sumie, Yasutaka Nakano, Tomoya Nagao, Shiho Tokumaru, Shotaro Michinaga